Recombinant Anti-IGFBP3 antibody [EPR18680-153] - BSA and Azide free (ab224530)


  • Product name

    Anti-IGFBP3 antibody [EPR18680-153] - BSA and Azide free
    See all IGFBP3 primary antibodies
  • Description

    Rabbit monoclonal [EPR18680-153] to IGFBP3 - BSA and Azide free
  • Host species

  • Tested applications

    Suitable for: WB, IPmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human IGFBP3 aa 1 to the C-terminus. The exact sequence is proprietary.
    Database link: P17936

  • Positive control

    • WB: Human serum.
  • General notes

    Ab224530 is the carrier-free version of ab193910. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.


    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    ab224530 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab224530 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 32 kDa (predicted molecular weight: 32 kDa).
IP Use at an assay dependent concentration.


  • Function

    IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
  • Tissue specificity

    Expressed by most tissues. Present in plasma.
  • Sequence similarities

    Contains 1 IGFBP N-terminal domain.
    Contains 1 thyroglobulin type-1 domain.
  • Developmental stage

    IGFBP3 levels are higher during extrauterine life and peak during puberty.
  • Domain

    The thyroglobulin type-1 domain mediates interaction with HN.
  • Post-translational

    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • Acid stable subunit of the 140 K IGF complex antibody
    • Binding protein 29 antibody
    • Binding protein 53 antibody
    • BP 53 antibody
    • BP53 antibody
    • Growth hormone dependent binding protein antibody
    • IBP 3 antibody
    • IBP-3 antibody
    • IBP3 antibody
    • IBP3_HUMAN antibody
    • IGF binding protein 3 antibody
    • IGF-binding protein 3 antibody
    • IGFBP 3 antibody
    • IGFBP-3 antibody
    • IGFBP3 antibody
    • Insulin Like Growth Factor Binding Protein 3 antibody
    • Insulin-like growth factor binding protein 3 precursor antibody
    • Insulin-like growth factor-binding protein 3 antibody
    see all


  • IGFBP3 was immunoprecipitated from 0.35 mg of human serum with ab193910 at 1/70 dilution. Western blot was performed from the immunoprecipitate using ab193910 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.

    Lane 1: Human serum 10 μg (Input).

    Lane 2: ab193910 IP in human serum.

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab193910 in human serum.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 seconds.

    The bands at 41 kDa and 44 kDa have previously been documented as IGFBP3 doublets (PMID:16816363).

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab193910).

  • Anti-IGFBP3 antibody [EPR18680-153] (ab193910) at 1/1000 dilution + Human serum at 10 µg

    VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/2000 dilution (VeriBlot for IP secondary antibody (HRP))

    Developed using the ECL technique.

    Predicted band size: 32 kDa
    Observed band size: 32 kDa

    Exposure time: 10 seconds

    Blocking and dilution buffer: 5% NFDM/TBST.

    This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab193910).


ab224530 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab224530.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact

Sign up